ENP Newswire - 11 February 2014
Release date- 10022014 - The University of Westminster has been awarded a research grant of EUR548,473 (GBP457,892) funded by the European Union to develop bioresorbable materials for arterial stent development for heart patients.
The grant is part of the EUR4,579,133 (GBP3,768,325) fund awarded to the 'Reinforced Bioresorbable Biomaterials for Therapeutic Drug Eluting Stents' (ReBioStent) project.
Arterial stents are small mesh tubes which are inserted to treat blocked arteries. The ReBiostent project started in January 2014 and will run for three years. It aims to produce coronary artery stent prototypes which will be biodegradable, with the ability to recover and maintain arterial shape and then gradually disappear. They will be manufactured using innovative materials, both natural and synthetic, and should be ready for clinical trials in December 2016.
Dr Ipsita Roy, Scientific Coordinator of the project, Head of Applied Biotechnology Research Cluster and Course Leader of MSc Applied Microbiology and Biotechnology at the University of Westminster, will lead the scientific aspects of the project, including the work involved in the development of the materials that will be required for stent development. The research is part of a multi-institution and multidisciplinary project in collaboration with 13 other European consortium members, of which the University of Westminster will be the Scientific Coordinator and Lucideon, the international materials technology company, will be the Coordinator.
Dr Ipsita Roy said: 'Doctors predominantly use permanent metallic arterial stents with polymer coating but they can cause adverse responses including inflammation and re-blockage of the arteries. Being able to create a completely biodegradable polymeric stent that recovers and maintains the shape of the artery and then gradually disappears would help to avoid any future complications. In addition to this, we will provide a technical framework and guideline for the production and manufacturing of highly functionalised active biomaterials which will be useful for the development of other medical devices as well.'
The University of Westminster is the Scientific Coordinator for the ReBiostent project. The other consortium members are:
1.Lucideon Ltd, United Kingdom (Coordinator)
2.Vornia Limited, Ireland
3.Spintec Engineering GMBH, Germany
4.Arterius Limited, United Kingdom
5.Politecnico di Torino, Italy
6.University of Southampton, United Kingdom
7.Friedrich-Alexander-Universitat Erlangen Nurnberg, Germany
8.Fundacion Tekniker, Spain
9.Fraunhofer IPA., Germany
10.The Chancellor, Masters and scholars of the University of Cambridge, United Kingdom
11.Ruhr-Universitaet Bochum, Germany
12.Life and Device SRL, Italy
13.Eurescom-European Institute for Research and Strategic Studies in Telecommunications Gmbh, Germany